According to Piper Jaffray, BioMarin Pharmaceutical BMRN is upgraded to Overweight.
Piper Jaffray said that $33 PT based on 37.5x the 2015 EPS ests (previously '14) of $1.93, disc at 30% (increased from 25% to reflect push out in valuation year). “PEG-PAL represents upside to Street estimates, with positive Phase II data in 2H paving the way for BMRN to start recognizing value for this program.”
BioMarin Pharmaceutical closed yesterday at $25.68.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in